BASF Names Markus Kamieth to Succeed Martin Brudermueller as CEO — Update
By Mauro Orru
BASF said Markus Kamieth would succeed Martin Brudermueller, who will step down as chief executive and chairman of the board of executive directors in April after almost six years at the helm of the German chemicals giant.
The company said Wednesday that Kamieth, who has been a member of the board of executive directors since 2017, would take charge at the end of BASF's annual shareholders' meeting on April 25.
"With Markus Kamieth, we have a highly competent and experienced successor, who has achieved excellent results for BASF during his diverse professional positions in Germany, the United States and Asia," said Kurt Bock, chairman of the supervisory board.
Brudermueller steered BASF through exceptionally challenging times marked by Russia's invasion of Ukraine and its implications for the energy market. Last year, BASF booked billions of euros in impairments from its shareholding in oil-and-gas producer Wintershall Dea, the deconsolidation of Wintershall Dea's Russian exploration and production activities, its European gas transportation business, the shareholding in Nord Stream and the financing of the Nord Stream 2 pipeline project.
Write to Mauro Orru at mauro.orru@wsj.com
(END) Dow Jones Newswires
December 20, 2023 05:55 ET (10:55 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks